ClinicalTrials.gg
RecruitingNCT03792919Updated Mar 24, 2025

Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)

A Phase 4 interventional study of Stop current treatment (anti-HBV neucleos(t)ides) and Keep current treatment (anti-HBV neucleos(t)ides) in Chronic Hepatitis B, sponsored by Humanity & Health Medical Group Limited. Recruiting at 1 site in Hong Kong. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by Humanity & Health Medical Group Limited · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2018; still recruiting 7 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Hepatitis B, Chronic with a site in Hong Kong — 8 open to participants now, 15 under way, none of them phase 3. Hepatitis B, Chronic · Hong Kong.

Planned enrollment
Largest of 79
2,000 · median 114
Started
2018
with 6 others
Phase 4
11 of 88
2 open now
Primary completion
2025-12
later than 2 of 14 live
Registered
47th of 88
by date

Among the 88 studies in Hepatitis B, Chronic with a site in Hong Kong, this one has the largest planned enrollment of the 79 interventional ones that give a count, is one of 7 that started in 2018, is one of 11 in phase 4, reaches primary completion later than 2 of the 14 other live ones, and was the 47th registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

8 of the 88 studies in Hepatitis B, Chronic with a site in Hong Kong are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Hong Kong have not opened yet or have stopped. Only those recruiting at a site in Hong Kong →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Hepatitis B, Chronic with a site in Hong Kong, or all of them as a file.
02

Study summary

To Identify the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance among chronic hepatitis B(CHB) patients.

Read the detailed description

Nucleos(t)ides analogues(NAs) is a safe and effective treatment among chronic hepatitis B(CHB) patients with excellent tolerance. Entecavir or tenofovir mono therapy has been shown to achieve inhibition of HBV replication in almost all adherent patients. However, HBsAg loss rate is low even after long-term NAs treatment. Recent studies indicated that cessation of NAs treatment could increase HBsAg clearance rate. Identifying the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance is very important.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. positive, HBeAg negative, antibody to HBeAg-positive;
  2. Stable administration of anti-HBV neucleos(t)ides analogue mono therapy for at least more than one and a half year;
  3. Demonstration of undetectable HBV DNA on three occasions, each at least 6 months apart, which is consistent with the APASL stopping rule;
  4. Patients read, understand the consent form, and signed the study consent.

Exclusion criteria

Exclusion Criteria:

  1. Patient with other liver diseases;
  2. Patient with concurrent hepatitis viruses or infection;
  3. Patients are reluctant to stop their anti- treatment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    Cessation of NAs treatment

    Chronic hepatitis B patients who meet the criteria to stop the current anti-HBV Neucleos(t)ides treatment will stop their NAs at the baseline of the clinical trial.

    Drug: Stop current treatment (anti-HBV neucleos(t)ides)

  • Active comparator
    Keep on current NAs treatment

    Chronic hepatitis B patients who meet the criteria to stop anti-HBV Neucleos(t)ides treatment will choose to keep on their current NAs treatment from the baseline of the clinical trial.

    Drug: Keep current treatment (anti-HBV neucleos(t)ides)

Interventions

  • DrugStop current treatment (anti-HBV neucleos(t)ides)

    Stop the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.

  • DrugKeep current treatment (anti-HBV neucleos(t)ides)

    Keep the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.

06

What researchers measure

Primary outcomes

  1. Incidence of HBsAg clearance

    The incidence of HBsAg clearance during the off-treatment period

    Time frame: From baseline to the end of the fifth year after cessation of anti-HBV treatment.

Secondary outcomes

  1. Incidence of HBsAg seroconversion

    The incidence of HBsAg seroconversion during the off-treatment period

    Time frame: From baseline to the end of the fifth year after cessation of anti-HBV treatment.

  2. Incidence of sustain HBV viral submission

    The incidence of sustain HBV viral submission during the off-treatment period

    Time frame: rom baseline to the end of the fifth year after cessation of anti-HBV treatment.

  3. Incidence of sustain biological response

    The incidence of sustain biological response during the off-treatment period

    Time frame: rom baseline to the end of the fifth year after cessation of anti-HBV treatment.

  4. Incidence of hepatocellular carcinoma

    The incidence of hepatocellular carcinoma during the off-treatment period

    Time frame: rom baseline to the end of the fifth year after cessation of anti-HBV treatment.

  5. Incidence of Liver failure

    The incidence of Liver failure during the off-treatment period

    Time frame: rom baseline to the end of the fifth year after cessation of anti-HBV treatment.

07

Study locations

1 of 1 sites recruiting
  • Humanity & Health Research Centre
    Hong Kong, Hong Kong SAR, Hong Kong
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2018 (actual). Primary completion is estimated for Dec 2025, 84 months after the start.

Of 46 non-industry phase 4 interventional studies under Hepatitis B, Chronic, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 83. This study's planned 84 months is above that.

Counting every sponsor, half of 63 studies reached it within 44 months; a quarter within 30 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 1, 2019
First posted
Jan 4, 2019
StartActual
Dec 1, 2018
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03792919
Lead sponsor
Humanity & Health Medical Group Limited
Responsible party
Sponsor
First posted
Jan 4, 2019
Start date
Dec 1, 2018
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Mar 24, 2025

Study contacts

George Lau, MD
Contact
gkklau@netvigator.com
852-28613777
Danny Wang
Contact
danny.wang@hnhmgl.com
852-28613777

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion